0001214659-15-003126.txt : 20150417 0001214659-15-003126.hdr.sgml : 20150417 20150416181531 ACCESSION NUMBER: 0001214659-15-003126 CONFORMED SUBMISSION TYPE: PX14A6G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20150417 DATE AS OF CHANGE: 20150416 EFFECTIVENESS DATE: 20150417 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES INC CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: PX14A6G SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 15776203 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: UAW Retiree Medical Benefits Trust CENTRAL INDEX KEY: 0001480561 IRS NUMBER: 900424876 STATE OF INCORPORATION: XX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: PX14A6G BUSINESS ADDRESS: STREET 1: 200 WALKER STREET CITY: DETROIT STATE: MI ZIP: 48207 BUSINESS PHONE: 313-324-5928 MAIL ADDRESS: STREET 1: 200 WALKER STREET CITY: DETROIT STATE: MI ZIP: 48207 PX14A6G 1 m416150px14a6g.htm m416150px14a6g.htm
 
 
Dear Gilead Sciences, Inc. Shareholders,   April 16, 2015
     
The UAW Retiree Medical Benefits Trust is sponsoring the specialty drug pricing risk assessment proposal that you will be asked to vote on at the Company’s upcoming annual meeting of shareholders on May 6, 2015.
 
We urge you to VOTE FOR PROPOSAL No. 8.

As long-term shareholders, we are concerned that Gilead's existing drug pricing strategy has created additional risks for Gilead in a rapidly changing business environment. Our proposal asks Gilead's Board of Directors to increase transparency around the Company's drug pricing strategies and report on the business risks these strategies may pose to shareholders in the face of rising payor, prescriber, and regulatory pressures to contain U.S. specialty drug costs.

GILEAD'S DRUG PRICING STRATEGY FOR HEPATITIS C DRUGS APPEARS SENSITIVE TO THE ACTIVITIES OF PAYORS, PRESCRIBERS, AND REGULATORS

· 
A number of public payors – including 28 states’ Medicaid programs – have placed significant restrictions on coverage primarily due to cost pressures. State Medicaid programs have felt pressured to use cost-control measures, such as limiting coverage to the sickest patients and requiring early viral response to continue treatment, to manage “the very serious cost implications” of breakthrough Hepatitis C treatments – specifically, Sovaldi.12 Texas, with the third-largest Medicaid population, did not purchase Sovaldi in 20143 and has sharply restricted coverage of Sovaldi and Harvoni for 2015.4 Given the large population of Hepatitis C patients reliant on public healthcare, these restrictions further reduce the potential patient population for Gilead's products.

· 
Gilead is facing increased scrutiny from lawmakers based on pricing concerns, patient access, and research and development costs inferred from the price Gilead paid for original Sovaldi developer Pharmasset. The U.S. Senate Finance Committee last year launched an investigation into Gilead’s pricing of Sovaldi, requesting such information as R&D costs including those borne by taxpayers, marketing expenses, and the $48,000 increase in Gilead’s pricing of Sovaldi as compared with the estimated price assigned by Pharmasset. The U.S. Senate Committee on Veterans’ Affairs also held a hearing on treating Hepatitis C in veterans that included testimony on the impact the costs of Sovaldi and Harvoni may have on patient access and the overall sustainability of the U.S. healthcare system.

· 
Sovaldi and Harvoni together accounted for over 50% of Gilead's total product sales in FY 2014.  If there is a disruption in Gilead's ability to market and sell its Hepatitis C portfolio products, Gilead’s “results of operations and stock price could be negatively affected.”5 Heavy reliance on Sovaldi and Harvoni for sales is concerning and some analysts are worried about the long-term sustainability of Gilead’s Hepatitis C drugs franchise, especially as new competitors enter the market.6
   
_____________________________
1 Letter from the National Association of Medicaid Directors to Congress re: Hepatitis C Treatment Costs (October 28, 2014). Available at http://medicaiddirectors.org/sites/medicaiddirectors.org/files/public/namd_sovaldi_letter_to_congress_10-28-14.pdf.
2 Christopher F. Koller, “Sovaldi Redux – The States Muddle Through,” Milbank Memorial Fund. Available at http://www.milbank.org/the-view-from-here/sovaldi-redux-the-states-muddle-through.
3 Joseph Walker, “Gilead’s $1,000 Pill Is Hard for States to Swallow,” The Wall Street Journal (April 8, 2015). Available at http://www.wsj.com/articles/gileads-1-000-hep-c-pill-is-hard-for-states-to-swallow-1428525426.
4 “Is the HCV Market as Big as Thought?” Company Update, Bank of America Analyst Report (April 10, 2015).
5 Gilead Sciences, Inc. Form 10-K for FY ending December 31, 2014 at 30.
6 Bank of America Analyst Report.
 
 

 

INCREASED TRANSPARENCY OF THE RISKS ATTENDANT TO GILEAD'S DRUG PRICING STRATEGIES WOULD ALLOW INVESTORS TO ANALYZE LONG-TERM BUSINESS RISKS

· 
The report requested by our proposal would help investors understand if and how the board fully considered the risks of a rapidly changing business environment and if the board's approach has shifted in light of the increased scrutiny from payors, prescribers, and regulators to Sovaldi and Harvoni.

· 
Gilead's stock price fell over 17% after Express Scripts – the nation's largest pharmacy benefit manager – announced that it would no longer cover Sovaldi and Harvoni in most cases.7

· 
Gilead states that “[a]ny change in the formulary coverage, reimbursement levels or discounts or rebates offered on our HCV products to payers may impact our anticipated revenues.”8

· 
Increased scrutiny from payors, prescribers, and regulators may adversely affect Gilead’s ability to introduce new products to market or increase sales of existing products. Gilead notes that “[i]f we do not introduce new products to market or increase sales of our existing products, we will not be able to increase or maintain our total revenues nor continue to expand our R&D efforts.”9

· 
Gilead’s 2014 10-K filing lists numerous risk factors related to the costs of its products but provides little insight regarding the Board’s business strategy to address these factors.

We therefore urge you to VOTE FOR PROPOSAL No. 8.

For additional information, please call (734) 929-5789.

Sincerely,

Meredith Miller
Chief Corporate Governance Officer
UAW Retiree Medical Benefits Trust

THIS IS NOT A PROXY SOLICITATION AND NO PROXY CARDS WILL BE ACCEPTED
Please execute and return your proxy card according to Gilead Science, Inc.'s instructions.
 
_____________________________
7 Michelle Fay Cortez, “Express Scripts Raises Pressure on Gilead for Drug Price,” Bloomberg (April 8, 2014). Available at http://www.bloomberg.com/news/articles/2014-04-08/express-scripts-raises-pressure-on-gilead-for-drug-price.
8 Gilead 2014 10-K at 30.
9 Gilead 2014 10-K at 31.
 
 

GRAPHIC 2 uawlogo1.jpg begin 644 uawlogo1.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4` M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@`` M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`#(` MM0,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_ MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($ M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B M7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X MN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$` M`A$#$0`_`/[^*,UA^)[2ZU#PUXAL+%2U[?:'JUG9J)!$6NKFPN(;=1*2HC)F M=`)"RA/O$C&:_-/PMXQ\;V7PE_9?\/\`AKPC\1=2^+/PIT"XT7Q7H&N>$_&& MG6VB^.+[X=:S\.-!'C+6-2T^/3KS21XTUZPU.YO8+S5(9="L;[Q%&[6EF9Z] M;+\JGF-*I.G7C"5.M&E*$HJT5/#8JM3JU*DJD8TJ4JV'AAG.2Y8SKP?-S0RFO1I5%J+ ME47*I3_4BBOQ?T#P9^T7\'?BU9^#=.T#QQK]QZWXFT)_AM\=I MYO$VG^+M5\33:7IVGW&M?!GXI:9XJN]01K2TNK?PYXKTRQC)M/*D?ZQ_99\" M>/\`1->O/!_CZR\2MH7[,TGBWX8_#/Q/XBFNY9OB-I'BS5;;7M(\9F>1]NIW M.@^`(O#?A">^?SU.KS^)4C,EC^':&"P]3%0S?"XJG&C3Q%.-*,/:U:% M7VL*<_9K$3LW6E@82@G.<(8R55JV$K1/'ROB[$9CBZ6"J9#CL'6EB*N$K3K2 MJ/#T,305"I5I^V>%I\R6'68U(57"G3J5,!"BI7QV'F?=V>`<'G'ZTM?D?JGA M;Q[:?M+^+/&&K>$/%UI\-HOVH$N+?QIX;T7Q/-XVLKP_!;PUI>C6,_E">&Y^ M`7BG7I]3L_%E[H]C=Q6GB2VMCJ'V:UN+B[MLOP_\/)]2_8/\:V5[X1FU#XO: M#\,;(P-P34=`@LO(BWF:W9)H9 M*V_U7HJG@ZDLVBXXJ>40?LL(JBH3S3VBFJLEBU&'U-PA[;VDJ=<:8F57'THY)*,L%3SVK'VN.E2>)IY,J#A*C"6`'K+F MG[*M[']A**_'GXO?"_QO:?'2QTSX:>`9?[%,W[-SZ7I^J:)XH?X7W%]#IOQW MF\06WB8Z1&85T=]2O?#T?BJ0,SV[WNDSZBD@$",GPJ\/:C8^,OV>(_$FA^,= M,TGP_P#"SXD:/XNL/BM\-?&_BNQ\/?$B?XT>'=8N/"&D6^B7<-AID.E*^I0_ M##Q-)>ZKI2>![2TFA^U1O/&E_P"JU!X:GB89JI^TH0Q'L8X13K1C/!5\8HRA M3Q=27/S4HX>UK>TG>_N\LI7&V)6,J82ID4Z>987+W*%6 MK@*4'#DQ$L4[R35*E:WO\\/V'HKX+_8+TNZT?X)?[7L]; M\#>+="\;6UDWQ#\97&DQ>*?%NO7#Z;XL+Z?V5>5!S5_95*D84_P![#X:D)4X3IS4H3A&<9111 M117`>H%%%%`!117P]\==?^*WQN\9ZC^SA\"/$$W@/2M)M[*3X]_&ZVC:6[\& M:?K%NMU8_#OP&`T:W/Q%UW2I4U/4;M9HX_"NAW5C<331WVJ6D:]V7X&6/K^R M]K2PU&G!UL5BZ_,J&$PT)1C.M4Y%*G"G2I4XRJUZU2G0I0E4J1B_-S7,H MY7AE6]A6QF)K5(X?`X##*+Q..QJ3^$[K5]0^(?Q&B=K?_A`?AY;1ZYJMK>X&RTUB^\Z M+2M)N&8[7LI+J?5HSR=,(9=WR[-^WC^VCXM3^T?AC^PAXN&AR_-:7GBI?%,D MUQ$<,K[8]'\/1;F1@0L#W"\AUD9>OWI\"_V4/@9^SOID5M\.O!.GQ:X5!U+Q MQKD<>N>.-9N6+--=7_B*]C:[B:X=V>2UTX6.GACN2S5OF/T=7T,$:N*Q511^*=[I?*2R;C?-;ULPXJ MI\/0GK#*^',OPF)=".\8U\WS:CB*N*JI>[4G0P6"HMWY*=K,_(!/^"AO[37@ M$"]^./[#WQ!T705*F[USPHNO-':1#!EG,6H:+>:>ZQCYB+C6K)?X&D4\U]M_ ML^?MC_`;]I6)[;X=>+1%XIMH7FU#P)XDA71/&-FD0_?RIIDLLD6IVT!!\Z\T M:ZU&U@X^T2PLP6OJ2OCSX[?L2_!SXT3Q>*].L9OA5\7-*G74O#7Q<^'")X?\ M5:5K$#&6VO=06P-I:^((TF(:9-1'VUH@T5MJ%IO9BI8[A7,_W6(R>KP]6E\& M/RO%8C&X2$GI'ZUEN-G4K2HK>4L)BHU8J[C2JM*$B.6<;Y,U6PF?T>*\/#6I ME>=8+"9=CJE-:R6"SC+H4:$<0]>2..P-2A-VC.O03=2/V'G-%?*?[.OQ+^(\ MM]K?P/\`C];V<'QJ\`6$.H0^)-+C\GPY\8/`,MQ]@TWXD^&4*IY%PMTJ:9XR MT/8DV@:W+;EHX[35;%1]65\YC<'5P.(GAZLJ=3EY9TZU&?M*&(HU(J=+$4*E MESTJL&IP;49J[C4A"I&4(_7Y=F%',\)3Q=&-6DI.<*N'Q$/98G"XBE)TZ^%Q M-*[]G7H58RIU$I2A)I3I3J4I0J2****Y#N,W6;&ZU/2=3TZRU:_T"\O["[L[ M77-*CTZ74]'N+B!XH=3T^+6+#5-*DO;&1UN;9-2TV_L7FC1;JSN8"\+_`(-? ML&?MO_M-)^VAK/[+G[7/Q"TWXA^$_COX#\?$/X<:\WA+3=(T[6?%$&F^&T\233/:1,+;2VN[6"VM]9AMX_W=\2:GJ& MBZ!J^K:3X>U+Q9J>G:?*M4^);>']9\*WFMI<7-KX!\56>J/HWB#2]/COO%GA M6WTB)+G2[]M1;]!X-625*99M3S#*<5E$,TK5LOI8O'5L%A/ MK2P694H8K+:-7+\3*ZR]XJM@*V8ULO6):J+%8>FZ;6C>WXK_`&U?VF?'?_!5 M?]FCX$^`?BA;>"?V1?C%:?':TTK3]`\'>!]6\5^.+O\`9JCU6R\8^*SXK\3Z M)XAN;'PQXJ^(FGZOX/TV/24MC<>%O"4VNZ;<6]QXAMM0A_8?X?\`[37[/?Q6 M\4ZSX(^&_P`9OASXW\6:#I]UJ^HZ%X<\4Z5J=\-&L=3FT34-:L8[>X9-7T33 M=:MY]'U+6-)>^TW3]5C;3;VZ@O<0'\6OVN?V%/V@?&'[67[->I?L^?!S7/#_ M`,!_V?OV4/V@/V6+;QS:?$#X:Z7X@L+GXT?"R_\``OA;QSX:T.\\76.OZII_ MA&_UB*^\87>HC1?$FI26>KWFD6>I7DEM)>^9_!+_`()X_M`:U^S;%\!?%?[( M>@?`3]H?X=?LG_%?]F'P_P#MBWW[3NK^//"\VG>*_!>H^%[9_@W\/=&\1>(- M8\-Z5\1+Z33]4\:V&LZ!X'T[PM!+JUUHEIJNJBPTZ#ZC,\EX+S;*,CQ=+-LM MRF=#)<)A:F'P-;((XNG5J9IGK_M3/:,L=A\9F&*67TLGCC:(S"FZ_M:>' M:<:$OG\OS3BK+I&&`RI++\GJ1P=7"X+"O M&3S%X6OB?98*<:?+*MS)U']?_%C]NUM9_P""C/[!GP@_9Y_:=\)>-_A/\7;_ M`..VB_''X9^%]-\#^)-/3_A7/PZUC7_#/BC3_'D>DW&O)97^OK=:?>MHVOW& MBR3^&!%#+;R?VG%=?9WP2_:KTG4?A'\0OB?\>_B[^RK:Z5X.^,/B_P`")XK^ M!_Q1N/%WPZLM)AO[$>!O#VO>)-%/@/\`MPZU\0?^"37BGQ%^QEI_@BT_8)T3XA?#;XLVNG?&OX/R MZ=X@T[7/@YH_PIT_Q/\`#.SL=3FGN_"TW]D#Q`NDZTNBZNTMRNBR:?;)"VN' MQ;P9^PI^W7\,['P;\2/!_P`!='NM1^!O_!4#XY?MGZ5^SWJ7Q%^&.E:3\6/@ M_P#'+06\-Z3;>'M7TW7-3\)^$_BU\*M-35)M,TKQ$NGZ%8WNOQ7.@Z_J$EM+ M;UKC.'>$<7@\NP4&5+V&$Q,:M9TL)CI9O/ZK1JTI8K%8;%0PU.E/&4DOWMN?VTOV2[3X86 M/QHG_:)^$:_"W4[_`%G2M/\`&D?C719](N]6\..R>(](A,%S)OQWNFB*VT+2=-O8 M+C2Q,VO7MGJ$]C;>+_M`?!+]IOXC^)?@YXJ^$7["G@SX*P>+[']I_0/C#K?A M?X@_!"P^._A*W^+OA;1[BWNIM>7[;\._#MG\7/'EA:WGQG\2>#K/XF?$R[\/ M^&;&STK6--U'5[F"O`?@'^R=^VOX/L?^".UCXP_9BU/3$_X)\3_&70OBY<6' MQ4^#%^NOZ-XW^'L_P[\.ZYX&M8?&\4NHK#=M)JNH:=J?]EWJZ)%!/&]SJ=ZV MG6_GY3P[PQ@Z$LRJ9IE-6M6P7$N'EE>9YQPYC70]MD7%-'*I\M.K*/UW#YO@ M,I>'Q5&?[VIC\+6ITL-2<95>_,,\S_%55@8Y=F5.G2Q>05HX_`95GV%C55/- M\@JYE'GJ4U+ZK5RS&9@JN'K4U[)83$4IU*U2+4/O#_@LO\=_CM^RW^QEXB_: M%_9^^*5W\.O&W@7Q9X#TDVDOA/P1XN\.>(M.\<>-?#_A:^77+#Q;H&JW4,VD MVE]<7FE7.CZAI@6Y:0:A'?0F(6_F7P9_:K^.&K?\%*?#/[-OPW^.VC_M=?LX MW?[/U]X_^.OB%?#OP\DU;]F[Q^T4S>#--N/B)\+--\.>'M5?Q[*_` MNL?;;_Q?X1\&^&_#ECX%\9>'_%=P^MW_`(FU:QO+B76(+":QTNWT6PU%Q M-_`MS\0_B'-\1O`DWA?1_AO:>'/A-KOB*+Q%X5\.ZU)/J@U_Q5JVF^5!JE]? M:-IUKJ-M;PW6G#4.&*W!^&P^:U>'L+C*\>.J=7'8O^R)X[!0_LO)*N0U\3A[ M+/:\Y8^EFE'*?J=6-:EB:KJ5:6)R_P!IAJN>?3XAI<4XBOE]/.\1@Z/^J52E M@\,\TAA,94^O9M3SFC1KW>44(K!U,MJ9@\73E0J4::A3G0QJ5>G^M&E?MC_L MI:UJ/BO2]-_:)^#L]WX(T74_$GB@OX_\.VMGI7AS1-5.A:WXADU*[OH-.N=! MT37!_8NLZQ8W=UIVE:NR:9J%Q;WSI`UKX=_M=_LN_%SQF/AW\+_V@/A)X^\< M/X8MO&L'A?PKXYT#6=7O/"=U#!<)X@T^ULKV5M1TN**YMVO+JP^TIIYE1+_[ M,YVU^!GPF_8$^.%G^RW:_!+XD?\`!.KPU=_'/X0?LP_&/]G?PO\`'34OVGM+ M\:>"/%,/CSP-K'@W2[[X0?#O7O%]]I_AA/&&L7GA_P`6^-[;Q;H7@C2/#']F MZMKFB0:IXFMM$T=>I\8?\$__`-JSQCH'_!-WP;HWPFN/AN_P`_82^/7[,'Q> M\;Z1XT^&`N/`WQ#^,OP1LO@[IGB;P_#IOBE=1\4Z%IWBC3+OQKXDO-*7^T1X M=UX7FGV>H>*'O])APK<&<$QJXFA'BI45&IF%&ABZ^:<.5Z%L'E^/QF%QGL\! MCL74Q6&S*KA<+A:5#FP>+HUL?&G*-2I1C'$ZPXJXM]G0J_ZN.MS0P52MAZ66 MY[0JMXG'X/"8C"*ICL+AX4*^!HXC$8NK7Y,5AJE+!RG"4857*C^Q_BC]O?\` M9.T/P3\7?&.D?'/X8^+C\&_`>M?$#Q)HVA>--%FO+K1=*N;O1[>XTF87#P:I MI^I^*K9?"%KK>E'4-)3Q)<0:3+="^=;=OS?_`&0OVXE^,VI?LU_M`_$K_@I' M\&?",/Q1^%_B[Q=\5_V(KW0?A7:V6C:C=:'J?BG1M,\#^*YIK#XH>'Y_A1H] MNW_":W_B35/%J^)3HUU=F#P_!?+9VODO[/\`^QO\<_#7P*T[PCXT_P""=^G^ M&?V@?A+^R3\2/V7]*^-4/[5%AXTTGQ99^*/!%SX%TRV^#7@W6O'-YI?ACPQX MMUBXTWQMXZLO&%KX%TKPI:6FKGPOI6OZT=,TV/J?A/\`L>_M3>#D_P""+T&L M_L_@R?L/_#WXO>"?C[?IXX^%-S]@U#QQ\(3\(-!N?#07Q4;GQ7H*ZP?^$QU0 MVWD7MMX=B1HM-N?$;#2%]&EDG!>6X3.,'1S'"U\15J8^E1QV+S3@_&5)8?"\ M.Y]B*,,%%/-:-*EF>84,OH4<;1G@\QP^*QV$A3Y*V%B\3QU,UXKQ];*\94P. M)I4J4MA:M/%8&O0PF);77B/4H-#OQ,OBC6? M"/AV_P#["N9/[<6R\<:EHEW=^"K:2QBUKQ!I+VUW!I44LK6\>/JOA'QA\:O@ MY\%I?V,?VD]!\&>$/%/Q6?XB_%?]H+P)#X3\=ZUXS\/01>*;KQCIOA6SUW1O M$7A+4==\7_$/^R_#^L3:_`P\'Z'IVI645I-?:39:77Y4?#3]BC]HS2?^">/P M$_9C^+G[._Q,\%^,/V8?C]J_CK_A;'[/OQ_^%_ASXGZ>TNN_&/7-*^.GP+O[ M[6UT75+SP]%XQT?3M=\%_$Y?#,^M^'-9\01Z2D6K6%H%_8S]@;P/\=/AY^R_ MX&\.?M&:_HOBKXI?VKXXUG4?$.DV/A6RO]:T+Q!XUU[6O".J>,YO`\$'A#5_ MB+J?AF^TN_\`'^O>'_M.G:QXKN=4ODU36I)9=9O_``,_RW(.'H8[&\/9KAL: M\/Q)B,%A,%B\;E.=4\3EU*GCH8',E1P^'J8?&0<(QQ4OK:H0P]3$T,//!8OW MJR]7),=G.?5,#AL^RZMA)5<@HXK$8O"X3-,IJX?'5:F`J8[`>VKUJ=7#2]HI M8;_976J8BGAZU:GB\/%^R?YF_"KXL_M5?$G]M;_@HI^R_P"+?VY?%_PZ^&W[ M*7@KX1ZUX+^);_#;]G&SU33#\1_!'[K3_#URAFM#'!H4 M$5E&WVVZR&EK[6_9_P#VZOV'OBCX6E\.^([[5I9?#^D>.)+P26%GIB>/;^P:\M;*>&R(U&]:RMH71K5YOC MGX9?LZ_M/Z%^VI_P4K^.WC+]EK5]1^%'[9/PP\#>#_`6E2^/_@CK6LQW_@'X M>WWA2:S\;>&;OQR--MM-\47LY>Q>/4-4BM;5HEUB"`R2B#SW3_\`@G;\?K__ M`((=7O[$]M\'/"G@C]J+P[X9\,V%S8W.O^`VT;XE:MX-^,VF?%P?8O'?AR_U M&$P:[8Q7&G:?=^*_[+>R\2&1;Z"WTU5U63Z+-,'PEF$LNP^+S')<#A:^(\/, M%6EDLN&,++"5,?P]3I<3YMB:^$HU,35I9?F<,0\PPLE&A]:K4JWM:$(MU/%R M[$\38&./Q&&P6:XW%4:'&V*HPS9<05X8J&$SN=7A_+:%+$U88>G4QN7NC'!8 MB+=;V%.I3E3K3]V/[>W7[2_[/=AXC^('A#4/C5\,]/\`%'PI\.+XP^)>@:AX MQT2QU;P+X4D:V2+Q)XIL;J\AGT;0YI+VTBM]4O4BLKB6YABAF>21%/S[\1/^ M"FO[#WPT\.>#/$^M?M`^!M1L/'GQ1TSX0:%!X?U6VU/4H/&-Y?Z5;:JGB'3_ M`#8+CPMI7@_3M7M/$?B_4_$*Z=#H_AXI>*MU<7FF6=]^6GQH_93_`&L/VAOC MK^T;\3_&O[&.J1_#'XY_L5?`OX)CP8?VC/A=X7^)^E^)/AI\:[?XCZLNE^)O M#NI:SI>B>,+&T@GU;P5=?:M0\*R^)-+\*#Q1=P:?>:SIVFT/$7[%_P"WBGP_ M^"GB?5M(\8_M'7WP,_X*7?"']I'PAHGQ:\2_!30_VI?$G[.W@GX97/A74K7X MJ^.=#U.W^&WC+Q]8^(K]K3PZ-4\6WVI)X)T_38;_`%6%HH=#TGR\#P=PUJY;AZM2A3Q=&&-HQ<,SJU*F\7'`Y'74(>W^KXFKDF<3;A#&U:<*L\-4EA*DD\#"%:G##_ M`%FK5KU'&I2PT(TXU_WT-IX0^+%G\,_BMX+US2M8CTR>'Q-X)\8Z-<1WVGZQ MX7\1V:V6N6=M?0!TO=#\2:+*DR*A:W?4K'1=3&9=/MY$]8KG=.UIT\.Z+JWB M73U\(7E_;:+'>:'?:AI]X^C:QK#VEI#H#ZAILTVF7UW%J5W%I<-H_A'3[ZZ1_'/PSF\(2V&_Q' M9:A:WWZ=U\[_`+4?[*_P3_;'^#_B#X(?'KPC!XJ\&:YY=W:3Q2?8?$?A/Q#: M+)_9'C#P7KT<;W?AWQ5HDLKRZ=JEJ&!5Y[&^@O=+O+ZPNO;R3%Y;2JU<'G5* MO/*L?&$,15PD82QV`K4W)X;,L'"I*%.M5PSG4A5PE6<*6,PE;$4/:X>O*AB\ M-Y.:X7&U84L7EE2E#,<$YRH4\0YQPF,I55%5\#BI04ITZ=?DISIXBG"53#8B MC0J\E6E&KAZWT117\T6I:3_P6R_X)A9T?X:V^G_\%0_V4-%S%X;L?$SW=K^T MGX)\/086TT6]NK"=O$FOR6%G;K;6U]8VGQ)M6B"M%I/AV)HM/AS;?_@YF^%/ MA&4:1\?OV(_VK?@[XHMRT&HZ/-IFA:BEM=H61H$/BJ7X>ZJY\Q2I$NC0LAR" M&*DU]IXK),QPGUJ$7K&&-R?&U<+FV!Q'+_$HUL( MXQ>D:U2/+.7S$O$3(L`W1XCAF'#&,AI4H9M@<2\/*2LI2PF982EB,OQE#F=H M5:==2DM94Z;YHQ_IOJI?W]CI5C>ZGJ=Y::=ING6EQ?ZAJ%_<0V=C86-G"]Q= MWM[=W#QV]K:6L$+[]C;Z0FHVJ6&D">0A8)[M?`VD_$&=[7Y@9A-1HI>NO\-?L: M_P#!3K_@IG?V.L?\%,?B%9?LQ?LK/=VVIR?L8?`;46TSQ%\1;..:*Y@T;XK> M+=.U75[VTT294C^WV-[XEUO49&22.U\/^$=0\O482?AIFN4+ZSQICLMX1P,/ M>G#%XW"8[.\2EO2RW(L!B*V,Q%>3]V+Q3P.$@VG6Q=*%Y*J?'V6YHU0X5PN. MXEQ4[*,\-A<3A,JP]]IX[-\90I8:C22NVJ"Q6(E;EIT)R:1^AOP1^/3?M[_' MZX\=?"N26Y_8N_9IUS5M-\._$,1/%IG[2O[1D<%SHM[JG@QY8P=5^$/P/TR[ MU."U\11XL/&7Q/UBVOM'>>R^'\-Y>_IQ7(>`/`'@KX5^"O"_PX^''A?1?!7@ M3P5HUEX>\*^%?#UC#IVC:'HVG1"&TL;&TA`2..-!ND=MTUQ.TES<2RW$LLC] M?7Q><8W"XS%)9=AIX/+,)36%R_#U9QJXE8>,G.5?&UH1A&MCL76E4Q.)G&,: M4)U/88:-/"4:%*G]3E>$Q.$P\GCL1'%9AB:CQ&-KTXRA0]M*,8*CA:VKN>)K5JDRBBBO*/2"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`*J75A8WP47ME:7@0Y075M#